Pharma Exclusives Pressreleases
Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic disease
Wednesday, May 14, 2025Septerna Incand Novo Nordisk today announced an exclusive global collaboration and license agreement to discover develop and commercialise oral small molecule medicines for obesity type diabetes and other cardiometabolic diseases
RYSTIGGO® (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support
Friday, May 09, 2025UCB a global biopharmaceutical company today announced that it has received approval from the Pharmaceuticals and Medical Devices Agency PMDA in Japan for athome selfadministration with infusion pump or a new manual push syringe method for RYSTIGGO r...
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
Wednesday, May 07, 2025Dr Falk Pharma a researchbased pharmaceutical company specializing in digestive and metabolic medicine today announced positive results from its pivotal phase trial NUC on norucholic acid NCA in primary sclerosing cholangitis PSC
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity
Tuesday, May 06, 2025Rocheannounced today the launch of its Elecsys PROC test a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunctionassociated steatotic liver disease MASLD
Lundbeck joins forces with Danish Centre for AI Innovation to improve brain health by advancing drug discovery with Gefion AI supercomputer
Tuesday, May 06, 2025H Lundbeck AS is pleased to announce its agreement with the Danish Centre for AI Innovation DCAI the company established to run and operate Gefion Denmarks flagship AI supercomputer
Vetter Prioritizes Continuity and Action in its Sustainability Efforts
Tuesday, May 06, 2025Vetter a leading global contract development and manufacturing organization CDMO published its fourth annual sustainability report The report shows that the familyowned business is actively pursuing ambitious sustainability goals
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
Monday, May 05, 2025Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Alvotech NASDAQ ALVO today announced that the US Food and Drug Administration FDA has approved SELARSDI
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
Wednesday, April 30, 2025Abivax SAa clinicalstage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases
Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Tuesday, April 29, 2025Boehringer Ingelheim reported new and updated data from the Beamion LUNG trial evaluating zongertinib in previously treated patients with HER ERBBmutant advanced nonsmall cell lung cancer NSCLC
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
Friday, April 25, 2025Rocheannounced today that the New England Journal of Medicine NEJM has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza baloxavir marboxil The trial met its primary endpoint
